Research analysts at StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) in a note issued to investors on Tuesday. The brokerage set a “hold” rating on ...

Vanda Pharmaceuticals connected this historical ... The company's common stock and Series A Junior Preferred Stock Purchase Right are both listed on the Nasdaq Global Market.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $18.0, a ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a pharmaceutical company with a market capitalization of $256.56 million and impressive gross profit margins of 93.62%, disclosed through a social media post ...

H.C. Wainwright maintained a Buy rating on Vanda Pharmaceuticals (NASDAQ:VNDA) with a price target of $18.00, representing significant upside potential from the current price of $4.31. According to ...

(RTTNews) - Vanda Pharmaceuticals Inc. (VNDA), a biopharmaceutical ... In premarket trading Monday, the stock is up 2.27% at $4.50. The views and opinions expressed herein are the views and ...

Also Read: Over 200% Stock Upside – Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst In September, the FDA issued a Complete Response Letter to the company.